Eli Lilly and Company $LLY Stock: Welch Group LLC Boosts Stake

Welch Group LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.9% during the 3rd quarter, Holdings Channel reports. The firm owned 16,100 shares of the company’s stock after buying an additional 1,036 shares during the period. Welch Group LLC’s holdings in Eli Lilly and Company were worth $18,629,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. Coastal Bridge Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $2,959,000. Birinyi Associates Inc. lifted its stake in Eli Lilly and Company by 32.6% in the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock valued at $1,689,000 after purchasing an additional 359 shares during the last quarter. Mosaic Family Wealth Partners LLC grew its holdings in Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after purchasing an additional 1,430 shares during the period. Moran Wealth Management LLC grew its holdings in Eli Lilly and Company by 85.6% during the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock worth $25,072,000 after purchasing an additional 9,638 shares during the period. Finally, Generali Investments Management Co LLC increased its position in Eli Lilly and Company by 17.5% during the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock worth $12,258,000 after buying an additional 1,521 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. This represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on LLY shares. UBS Group upped their price objective on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a research note on Friday. Wall Street Zen upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday. Cantor Fitzgerald boosted their target price on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an “overweight” rating in a report on Monday. TD Cowen restated a “buy” rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Finally, HSBC raised their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,404.14.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Another strong quarter and higher guidance: Third-quarter revenue rose roughly 39% year over year to $24.4 billion, beating expectations, while adjusted EPS also exceeded estimates. Strong demand for Mounjaro and Zepbound led Lilly to raise its full-year outlook. Eli Lilly Just Delivered Another Blowout Quarter
• Positive Sentiment: Analyst price-target increases: Cantor Fitzgerald raised its target to $1,600 and maintained an “overweight” rating. Other firms, including JPMorgan, also boosted targets, reflecting continued confidence in Lilly’s earnings outlook. Cantor Fitzgerald price target
• Neutral Sentiment: Commercial reorganization: Lilly is combining its U.S. and international commercial operations into one division. The move could improve coordination and execution globally, but its financial effect is not yet clear. Lilly combines commercial divisions
• Negative Sentiment: Pricing and growth concerns: Medicare’s GLP-1 Bridge program and lower realized drug prices may pressure revenue and margins. Analysts also warn that growth could moderate after exceptionally strong results, while one-time revenue benefits may not recur. Lilly’s First Full Medicare Quarter
• Negative Sentiment: High expectations and concentration risk: With about two-thirds of revenue tied to its leading GLP-1 medicines and the shares trading at a premium valuation, investors may be taking profits and demanding evidence that rapid growth can continue. Eli Lilly: Softer Growth Ahead

Eli Lilly and Company Stock Down 0.4%

Eli Lilly and Company stock opened at $1,412.06 on Tuesday. The stock has a market cap of $1.33 trillion, a P/E ratio of 45.83, a P/E/G ratio of 1.73 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,449.68. The company’s 50-day moving average price is $1,200.81 and its two-hundred day moving average price is $1,094.25.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter in the previous year, the company posted $7.02 earnings per share. The business’s revenue was up 38.6% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 35.18 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.